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EDITORIAL REVIEW
Disturbed volume homeostasis in patients
with cirrhosis of the liver
Cirrhosis of the liver is one of the leading causes of death in
men during the age of productive employment [1, 21. Thus, the
socio.economic cost of cirrhosis to the patient, his family, and
society is incalculable. While the clinical manifestations of
cirrhosis have been amply documented, the pathogenesis of the
perplexing and common complication of disturbed volume
control in this disease has remained elusive. The purpose of this
communication is to critically analyze the current view of the
mechanism of the circulatory impairment in cirrhosis. It is
hoped that a clearer understanding of this disorder in cirrhosis
may improve the management of these patients.
Patients with moderately advanced cirrhosis often show a
characteristic circulatory disturbance, consisting of a tendency
to arterial hypotension and avid sodium retention by the
kidneys which may lead to edema and formation of ascites. It is
these patients rather than those with the so-called hepatorenal
syndrome who will be the primary subject of this review. It is,
however, likely that patients with hepatorenal syndrome merely
represent the extreme spectrum of disturbance of volume
control observed in all cirrhotic patients with ascites and renal
sodium retention.
Afferent factors in volume control in cirrhosis
(I) Traditional (underfilling) theory of the disturbance in
volume regulation. In its original formulation this theory fo-
cused on formation of ascites as the primary and central event
in a chain that signaled the kidney to retain salt and water [3, 41.
According to this theory, decreased synthesis of albumin by the
diseased liver led to reduced plasma oncotic pressure and
intrahepatic venous obstruction raised the hydrostatic pressure
in the portal-splanchnic vascular bed. The resulting alteration in
Starling forces in the porto-splanchnic bed led to increased
formation of lymph. Once the increased formation of lymph
exceeded the capacity of the lymphatic system to return it to the
venous system, lymph would spill into the peritoneal cavity and
form ascites [51- It should be noted that rates of lymph flow in
the cirrhotic patient may increase to approximately tenfold
greater than the normal rate.
In the context of this traditional theory, the accumulation of
ascites is thus viewed to occur at the expense of the systemic
circulation which is thereby depleted. Such volume contraction
then presumably activates neurohumoral signals to the kidney
to retain salt and water.
This traditional theory of volume regulation in cirrhosis,
however, may be modified by including other intravascular
factors which are operant in patients with cirrhosis. These
factors also cause a relative decrease in the circulatory arterial
blood volume as compared to the vascular capacity of the
circulation (Table 1) [61. This discrepancy has been referred to
by some authors as a decrease in effective" blood volume.
Some of these factors are anatomical, whereas others are
functional. Thus, in human cirrhosis [7, 81 and canine toxic
cirrhosis [9] there may be a great increase in the vascular
capacity of the splanchnic and pulmonary [101 circulation.
When widely developed, these vascular changes may assume
the proportion of arterio-venous shunts [91 and may contribute
to the reduced systemic vascular resistance that is characteris-
tic of patients with cirrhosis [11, 121 and animals with toxic
cirrhosis [13] or with chronic bile duct ligation [14]. This
vascular disorder is further compounded by impairment of
autonomic reflex vascular responses [15], diminished pulmo-
nary vasoconstriction in response to anoxia [10] and impaired
pressor response to exogenous angiotensin II and noradrenaline
[16]. Similar blunting of the pressor response to vasoactive
agents is also seen in the dog with chronic bile duct ligation [17]
and during pregnancy [18].
Because of the sequestration of fluid in the peritoneal cavity
and the generalized loss of intravascular fluid into the intersti-
tial compartment, that is, peripheral edema, which occurs
secondary to (1) portal hypertension, (2) reduced plasma oncot-
ic pressure, (3) the gross enlargement of the capacity of the
vascular bed, and (4) the loss of the normal vasoconstrictor
response to a wide spectrum of neurohormonal stimuli, it is
clear that patients with cirrhosis may have impaired central
hemodynamics. In addition, in some patients with cirrhosis, left
ventricular function is impaired [12, 19] and in others tense
ascites reduces venous return (preload) to the heart [20]. With
this background it is not surprising that patients with cirrhosis
tolerate hemorrhage or fluid loss poorly.
Other support for the traditional "underfihling" theory in-
cludes salutary improvement in volume homeostasis following
volume replenishment in these patients. For example, volume
expansion may suppress the renin-angiotensin-aldosterone
axis, increase the glomerular filtration rate (GFR), and cause a
natriuresis and a negative salt balance in patients with cirrhosis
[21]. Among the volume expansion maneuvers that have been
found to increase sodium excretion are acute volume expansion
with reinfusion of ascitic fluid [11, 12, 21, 22], introduction of
the peritoneo-jugular LeVeen shunt [23—28], "neck out" im-
mersion which increases central blood volume [29—3 1], surgical
revision of the thoracic duct-venous junction to facilitate lym-
phatic return [5, 32], and infusion of metaraminol to overcome
the peripheral vasodilatation [33]. Similarly, normalization of
Starling forces by surgical decompression of the portal bed in
certain patients with cirrhosis may be associated with mobiliza-
tion of the ascites, improvement in kidney function, and diure-
sis [34, 35]. Note that all these maneuvers may overcome the
circulatory disturbance without improving the function of the
cirrhotic liver.
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Taken together, the findings mentioned above are compatible
with the view that a discrepancy between the circulating
volume and the vascular capacity, that is, "underfihling" [6,
141, is the primary cause of renal sodium and water retention in
patients with cirrhosis. Such a view includes increased vascular
capacity (peripheral vasodilatation and arteriovenous shunts)
with "redistribution" of fluid into the interstitium and venous
portion of the circulation in addition tO ascites formation in the
peritoneal cavity.
Critique of the "underfihling" concept in cirrhosis. As de-
scribed in the previous section, many patients with cirrhosis
show clear signs of volume depletion, which may be aggravated
by vomiting, occult variceal bleeding, and excessive use of
diuretics. Although, as described above, there may be dramatic
improvement and natriuresis following volume repletion by
several diverse measures, such improvement is at best tempo-
rary, and moreover, it occurs only in certain patients. Thus,
only approximately 30 to 50% of cirrhotic patients may exhibit a
natriuresis during volume expansion [11, 121 or immersion [29—
311 although the latter procedure effectively suppresses the
renin-aldosterone-angiotensin axis. Similarly, surgical portal
decompression in human cirrhosis is not always associated with
improvement in kidney function and diuresis [331. Some of the
variability in response could be due to the fact that the degree of
volume replenishment achieved was adequate in some patients
and inadequate in others. Nevertheless, it appears that "under-
filling" cannot be the entire explanation for the renal sodium
and water retention which characterizes the cirrhotic patient.
Moreover, it may occur only in a certain proportion of patients
with cirrhosis, perhaps at specific stages of their disease. In this
respect, the results of the study of Tristani and Cohn [111 are
revealing. They studied 21 patients with decompensated alco-
holic cirrhosis. Thirteen patients had a low or normal cardiac
index and eight had an increased cardiac index. The patients
with the low cardiac index responded to volume expansion with
dextran with an increase in cardiac output, 148% increase in
renal blood flow, and a rise in the proportion of cardiac output
delivered to the kidneys (renal fraction). The 13 patients with
the initial normal or high cardiac index responded to dextran
infusion with only a slight increase in cardiac index and renal
blood flow.
The authors concluded that in the group with initial high or
normal cardiac index "volume depletion was apparently not an
important factor in their oliguric state . . . ,a mechanism other
than volume depletion may contribute to renal vasoconstriction
in some patients with liver failure" [111.
In this respect, it is interesting to compare systemic and renal
hemodynamics in three dog models which manifest avid renal
salt retention. On the one hand, the dog with constriction of the
inferior vena cava represents a model of "pure" central volume
depletion (underfilling) with minimal liver damage except for
venous congestion. On the other hand, both the dog with
chronic bile duct ligation [14, 36] and the dog with dimethylni-
trosamine-induced cirrhosis [131 also retain salt and water, but
differ from the caval dog since advanced parenchymal liver
damage is present. The caval dog with "underfilling" of the
central circulation has, as expected, a reduced cardiac output
[6, 37] and increased peripheral vascular resistance [6, 37, 38].
Intrarenal administration of vasodilators or alpha-adrenergic
blockade results in natriuresis [39—40]. In contrast, the dog with
Table 1. The modified "underfilling" concepta
Possible etiologic factors causing "underfilling" of the circulation in
patients with cirrhosis and animals with experimental liver damage
(1) Peripheral vasodilatation and blunted vasoconstrictor response to
reflex, chemical, and hormonal influences.
(2) Opening arteriovenous shunts, particularly in the portal circulation.
(3) Increase in the vascular capacity of the portal as well as the
nonportal circulation.
(4) Impaired left ventricular performance.
(5) Diminished venous return secondary to advanced tense ascites.
(6) Occult gastrointestinal bleeding from ulcers, gastritis, or varices.
(7) Volume losses due to vomiting and excessive use of diuretics.
This concept perceives "underfiuing" mainly as a discrepancy in
the relation of the arterial vascular capacity to circulating blood
volume. Under this formulation ascites formation secondary to excess
lymphatic formation need not be the initial or primary event in causing
the "underfilling" of the circulation.
toxic cirrhosis and the dog with chronic bile duct ligation both
have increased cardiac output [13, 14] and diminished peripher-
al resistance [13, 14]. Intrarenal infusion of vasodilators or
alpha-adrenergic blockade does not result in natriuresis in spite
of renal vasodilatation [41, 42]. Thus, the systemic hemody-
namic and renal vascular responses in dogs with bile duct
obstruction or cirrhosis differ strikingly from the responses in
dogs with uncomplicated "underfilling" of the circulation sec-
ondary to caval constriction.
Finally, any "underfilling" in cirrhotic patients could be, at
least in part, due to a reduction in the nonsplanchnic blood
volume. This, however, has not yet been demonstrated either in
human cirrhosis or in experimental canine cirrhosis. If any-
thing, indirect measurement in human cirrhosis [7, 8] and direct
measurement in the dog with toxic cirrhosis [7] show an
increase in absolute nonsplanchnic blood volume during salt
retention. This, of course, does not exclude a relative decrease
in nonsplanchnic arterial blood volume which occurs secondary
to an increase in vascular capacity during peripheral vasodila-
tion. Nevertheless, the above information suggests that isolated
volume depletion (underfilling) cannot account for the entire
spectrum of the disturbed volume control in patients and
animals with liver damage. There arises the need, therefore, to
re-examine the traditional "underfilling" concept in cirrhosis.
(2) "Overflow" concept of ascites ftrmation in cirrhosis
(Table 3). The traditional "underfilling" view (Tables 1 and 2)
has been challenged recently and an "overflow" concept of
ascites has been proposed. Based on experiments on patients
with cirrhosis, Liberman, Ito, and Reynolds [7] and Lieberman,
Denison, and Reynolds [8] postulated that nonvolume depen-
dent renal sodium retention was the primary disturbance in
sodium homeostasis in cirrhosis. In their view this renal sodium
retention led to total plasma volume expansion including its
nonsplanchnic component. The predilection of the renal salt
and water retention to cause ascites was explained by the local
alteration of Starling forces in the portosplanchnic bed (over-
flow concept). This formulation of the "overflow" concept was
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Table 2. Experimental evidence supporting the "underfilling" concept
in cirrhosis
(1) Acute central hypervolemia induced by neck-out water immersion
of patients with cirrhosis may be associated with an increase in
diuresis and natriuresis, increase in GFR and suppression of
elevated levels of plasma renin activity and plasma aldosterone.
(2) Acute volume expansion in patients with cirrhosis may be
associated with an increase in cardiac output, renal blood flow,
glomerular filtration rate, and free water clearance.
(3) Peritoneovenous (LeVeen) shunting in cirrhotic man or dog may be
associated with improved systemic hemodynamics, mobilization of
the ascites, increase in GFR and suppression of the elevated plasma
renin activity and plasma aldosterone levels. Similar results may be
obtained by portocaval shunting in man with cirrhosis.
(4) Re-anastomosis of thoracic duct to the venous system in patients
with cirrhosis may be associated with mobilization of the ascites
and diuresis.
Table 3. Experimental evidence supporting the "overflow" theory in
cirrhosis
(1) Ascites may accumulate in patients with compensated cirrhosis
following increased renal salt and water retention and hypervolemia
associated with mineralocorticoid administration.
(2) As estimated by available methods, nonsplanchnic plasma volume
in patients with cirrhosis does not decrease during formation of
ascites and does not increase during spontaneous diuresis.
(3) In dogs with toxic cirrhosis renal salt and water retention precedes
formation of ascites.
(4) In dogs with toxic cirrhosis elimination of the ascites with
peritoneovenous LeVeen shunt does not prevent renal salt and
water retention when the diet contains liberal amounts of sodium
chloride.
(5) In animals with experimental liver damage and in patients with
advanced cirrhosis renal sodium retention may still persist after
effective blood volume has been replenished.
based on several indirect observations. First, in contrast to
normal subjects patients with compensated cirrhosis accumu-
late ascites under the influence of exogenous mineralocorti-
coids [8]. Such loss of mineralocorticoid "escape" in patients
with cirrhosis has later been confirmed by others [43]. More
importantly, spontaneous diuresis and natriuresis have been
found to occur independent of measurable changes in the
volume of the nonsplanchnic vascular compartment [7, 8]. This
contradicts the original "underfilling" concept which requires
absolute or relative contraction of nonsplanchnic plasma vol-
ume with formation of ascites during the sodium retaining
period and expansion of these compartments during diuresis.
Strong support for the "overflow" theory came from the
extensive and carefully planned experiments by Levy [9, 13,
46], Levy, Wexler, and McCaffrey, Levy and Wexler [441, and
Levy and Allotey [45]. These authors studied sequentially the
events that led to sodium retention and ascites following the
institution of dimethylnitrosamine cirrhosis in the dog. They
were also able to measure directly the changes in the volume of
the vascular compartments following salt retention. The study
indicated that renal sodium retention and volume expansion
may precede formation of ascites by 10 days. (As little as 25 ml
of ascites were detectable by needle aspiration of the peritoneal
cavity.) Moreover, one third of the total increment in blood
volume occurred in the nonportal compartment suggesting an
increase in central ("effective") blood volume. The sodium
retention was reported to occur independent of changes in
cardiac output, mean arterial pressure, splanchnic blood vol-
ume, hepatic arterial blood flow, GFR, renal blood flow,
intrarenal hemodynamics, aldosterone, estrogen and progester-
one levels, and increased renal sympathetic nerve activity [13].
Prevention of portal hypertension by prior construction of a
portocaval fistula before induction of cirrhosis did not prevent
formation of ascites [44]. Under this experimental provision the
entire increase in plasma volume was confined to the nonportal
compartment. Also, elimination of ascites in these cirrhotic
dogs with the LeVeen shunt [33] did not prevent salt retention
during liberal salt intake. Taken together, therefore, these
studies support the view that the initiating event in the renal
sodium retention of cirrhosis is not related to "underfilling,"
thus primary renal sodium retention has been suggested (over-
flow theory). One word of caution, however, should be sound-
ed. An important, although undetectable, increase in vascular
capacity, that is, peripheral vasodilatation, could have triggered
the early sodium retention because cardiac output measure-
ments, which are necessary to calculate peripheral vascular
resistance, may not detect modest but critical changes in the
range of 10%.
There are several additional hepatorenal influences that are
apparently independent of systemic volume status and thus
support the overflow theory. Hepatic venous congestion is a
stimulus for aldosterone secretion and renal sodium retention
[471; acute portal hypertension in the dog also causes renal
sodium retention which is reversed at least in part by renal
denervation [48]. A fall in cardiac output may, however, occur
in this latter model. The conscious rat with chronic bile duct
ligation also has diminished renal blood flow and increased
renal vascular resistance in the face of normal systemic hemo-
dynamics, plasma protein concentration and plasma volume
[49]. These results, therefore, suggest that renal sodium reten-
tion may precede alterations in systemic hymodynamics and
ascites formation. The mechanism remains to be defined,
however, whereby renal sodium retention may initiate volume
expansion and "overflow" ascites.
Critique of the "overflow" theory. The "overflow" theory is
useful in alerting physicians and investigators to the possibility
that in cirrhosis the kidneys may avidly retain sodium and water
as a response to stimuli that are independent of volume status.
Nevertheless, this concept does not explain why some of these
patients and experimental animals exhibit a natriuresis in re-
sponse to volume expansion or neck immersion. Also, the
"overflow" theory cannot account for the stimulation of the
renin-angiotensin-aldosterone axis [31, 50—54] and increase in
plasma arginine vasopressin [55] and catecholamines [561 in
patients with cirrhosis. Rather, volume expansion should sup-
press these parameters.
If a true and prolonged pure "overflow" situation was
common in cirrhosis, a clinical profile resembling "low renin
hypertension" would be expected to be seen, at least during an
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early state of development in patients with cirrhosis or dogs
with induced liver damage. Such a profile has not been de-
scribed in association with cirrhosis, independent of the stage of
development. In fact, liver disease in dogs leads to hypotension
[14] and correction of previously induced renal hypertension
[571.
Levy and Allotey [45] studied the temporal relationship
between renal salt retention and alteration in systemic hemody-
namics in dogs with a model of toxic cirrhosis. They interpreted
their findings as demonstrating that renal salt retention and
ascites occurred before ascites formation and any change in
systemic hemodynamics. These findings were thus taken as
evidence supporting the "overflow" theory. Inspection of their
data, however, reveals that mean blood pressure decreased
from 120 mm Hg before cirrhosis was induced in the dogs to 110
mm Hg when the cirrhotic dogs were in a 20 mEq/day positive
sodium balance. Moreover, the most profound positive sodium
balance was observed only after a substantial decrease in
peripheral vascular resistance occurred. Therefore, as the au-
thors themselves suggested, "the possibility that such urinary
salt retention is secondary to subtle decrements in arterial
fullness has not been excluded completely" [451. In this con-
text, it is interesting to note that experimental animals with liver
damage may have blunted pressor response to volume chal-
lenge indicating increased compliance [14] and susceptibility to
shock following controlled hemorrhage [58]. Such important
but subtle evidence of underfihling may not be significantly
detectable by monitoring blood pressure and cardiac output for
I or 2 hr per week. Such underfilling, however, may be
"sensed" and signal the kidney to retain salt and water.
Moreover, the following phenomena in human or experimen-
tal cirrhosis are not normally present in pure "overflow"
situations: (1) opening of extensive A-V shunts and (2) impaired
vasoconstrictor response to diverse neurohormonal, chemical,
or volume stimuli.
Thus, it is obvious that neither the "underfilling" nor "over-
flow" theory can account exclusively for all the observed
derangements in volume regulation in cirrhosis. Rather, it is
quite possible that elements of the two concepts may occur
simultaneously or sequentially in patients with cirrhosis. At
present, therefore, it can be suggested that in cirrhosis the
kidney responds to volume-independent and volume-dependent
stimuli with avid sodium retention. Formation of ascites cannot
be viewed as a primary or central event causing "underfihling"
and initiating this perturbation in sodium balance. On the other
hand, classic "overflow" phenomena such as an increase in
blood pressure and a suppression of volume-sensitive hormone
systems (plasma renin activity, aldosterone, arginine vasopres-
sin, catecholamines) are conspicuously absent in patients with
cirrhosis and in animals with experimentally induced liver
damage.
Efferent factors in the volume control in cirrhosis
(1) Role of the renin-angiotensin-aldosterone axis. The renin-
angiotensin-aldosterone axis is often stimulated in patients with
moderately advanced cirrhosis [31, 50—53]. The initial causative
factors for this stimulation could be arterial hypotension, de-
creased "effective' blood volume [14], hepatic venous conges-
tion [47], portal hypertension [48], adrenal venous congestion
[59], or diminished distal delivery of sodium chloride to the
macula densa.
In some patients with cirrhosis [51], but not in others [52],
administration of angiotensin II antagonists results in arterial
hypotension [51]. This finding suggests that the renin-angioten-
sin system may be activated in defense of arterial blood
pressure in cirrhosis [51].
Bosch et a! [53] and Arroyo et a! [54] have recently shown in a
large group of patients with cirrhosis but without azotemia that
activation of the renin-angiotensin-aldosterone axis in cirrhosis
is a late and ominous prognostic sign (50% survival 6 months)
and is associated with avid sodium retention and increased
wedged hepatic venous pressure. Interestingly, inulin clearance
in these patients was normal, thus demonstrating that the early
avid sodium retention is due to increased tubular sodium
reabsorption rather than a fall in GFR.
In cirrhotic patients the increased plasma renin activity can
be decreased into the normal range by salt loading or neck out
water immersion [31]; however, a natriuresis following these
maneuvers does not always occur [31].
Epstein et al [31] assessed the role of hyperaldosteronism in
the salt retention of cirrhosis by subjecting cirrhotic patients to
the aldosterone antagonist before and after water immersion.
Spironolactone administration without water immersion result-
ed in only modest natriuresis. In contrast, when patients on
spironolactone were immersed they demonstrated a substantial
increase in sodium excretion. The finding that this natriuresis
was also associated with an increase in free water clearance and
potassium excretion, indicated that water immersion increased
solute and water delivery to the distal nephron. Thus, both
decreased distal delivery of sodium and aldosterone-mediated
enhanced distal reabsorption of sodium may be involved in the
renal sodium retention in the cirrhotic patient.
It must be emphasized, however, that administration of
spironolactone alone (400 mg/day for at least 2 weeks) can
effectively induce a natriuresis and abolish the ascites in a great
many patients with cirrhosis [60—62]. Similarly, diuresis and
loss of ascites also have been observed in the dog with bile duct
ligation after adrenalectomy and replacement therapy with
physiological doses of glucocorticoids and mineralocorticoids
[63]. Finally, there is a possibility that during liver disease the
renal tubule becomes supersensitive to the sodium retaining
influence of aldosterone and thus the patient fails to "escape"
from the sodium-retaining effect of the hormone [64] (Table 4).
In summary, clinical experience suggests that in early and
moderately advanced cirrhosis, hyperaldosteronism associated
with impairment of the "escape phenomenon" is of major
importance in sodium retention and ascites formation. When
the liver disease progresses further, additional antinatriuretic
influences become operative. At this latter stage of cirrhosis
distal delivery of sodium declines, probably secondary to a fall
in GFR and an increase in proximal tubule reabsorption, and
spironolactone alone becomes less effective in alleviating the
ascites and edema.
(2) Role of increase in sympathetic nervous activity in the salt
retention of cirrhosis (Table 5). If "underfilling" of the circula-
tion supervenes in cirrhosis, the adrenergic nervous system
may be activated [30, 56]. Such an increase in sympathetic tone
could contribute to the antinatriuresis of cirrhosis by decreasing
total renal blood flow, or its intrarenal distribution, or by acting
directly at the tubular epithelial level to enhance sodium
reabsorption [65]. Recently, patients with advanced cirrhosis
have been found to have strikingly elevated concentrations of
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Table 4. Aldosterone and sodium retention in liver disease
Evidence for a role for hyperaldosteronisrn in sodium retention
associated with liver disease
(1) Diuresis and total abolition of ascites may occur in some patients
with cirrhosis following treatment with spironolactone, and in dogs
with chronic bile duct ligation following adrenalectomy and
physiologic hormonal replacement.
(2) There is an increased tubular sensitivity to the salt-retaining action
of aldosterone in patients with cirrhosis.
Evidence against a role for hyperaldosteronism in sodium retention in
patients with cirrhosis
(1) Dissociation between increase in plasma aldosterone and sodium
retention.
(2) Dissociation between plasma aldosterone suppression and
natriuresis.
Potential renal vasoconstrictor
influences in cirrhosis
(1) Activation of intrarenal
renin-angiotensin system
(2) Increase in circulating
catecholamines and
arginine vasopressin
(3) Increase in sympathetic
(4) Endotoxemia
(5) Decrease in circulating
kallikrein
Potential renal vasodilatory
influences in cirrhosis
(I) Increased intrarenal
synthesis of
vasodilating
prostaglandins
plasma catecholamines [56]. The patients also had profoundly
increased plasma concentration of plasma renin activity, aldos-
terone, and arginine vasopressin. Moreover, the plasma levels
of catecholamines correlated closely with the degree of sodium
and water retention. It seems likely that such an increase in
adrenergic activity may also contribute to the support of arterial
pressure in cirrhotic patients. This speculation is supported by
the extreme sensitivity of some patients with cirrhosis to the
hypotensive action of phentolamine [66]. The finding of in-
creased endogenous plasma catecholamine levels in cirrhotic
patients may explain the blunted pressor response to noradren-
aline observed in patients with cirrhosis [16] and dogs with
chronic bile duct ligation [17].
Cardiovascular responsiveness to reflex autonomic stimula-
tion may be impaired in patients with cirrhosis. This includes
impaired vasoconstrictor response to a variety of stimuli such
as ice on the forehead, mental arithmetic, lower body negative
pressure, and the Valsalva maneuver [15]. This widespread
interference in the peripheral and central autonomic nervous
system in cirrhosis could be explained partially by increased
occupancy of endogenous catecholamine receptors.
The presence of false neurotransmitters," mainly octopa-
mine, in the central and peripheral nervous systems has been
invoked to explain the autonomic dysfunction, the hepatic
coma including extrapyramidal changes, as well as the peripher-
al vasodilatation of cirrhosis [67, 68]. According to this concept,
the precursors of false neurotransmitters are produced in the
bowel by bacterial degradation of protein. These compounds
are usually cleared by the healthy liver, mainly with catabolism
by monoamine oxidase. However, in cirrhosis these com-
pounds may bypass the liver and enter the nervous system
where they are degraded locally by beta-hydroxylation by
relatively nonspecific enzymes. In the central nervous system
they may replace normal neurotransmitters and thus interfere
with normal synaptic transmission [67, 68].
In far advanced liver disease when the patients are frankly
hypotensive, cirrhotic patients may have a characteristic pat-
tern of blunted pressor response to tyramine and supranormal
pressor response to exogenous noradrenaline suggesting tissue
depletion of catecholamines resembling that seen after adminis-
tration of reserpine [69].
Intrarenal alpha adrenergic blockade in the human has failed
to relieve the intense vasoconstriction in patients with cirrhosis
[66]. Also, renal denervation or alpha adrenergic blockade does
not abolish the antinatriuresis associated with various experi-
mental models of liver injury in the dog [41]. Therefore,
increased adrenergic tone cannot entirely account for the
antinatriuresis of cirrhosis.
In summary, patients with cirrhosis and animals with experi-
mental liver damage suffer from a widespread central and
peripheral autonomic dysfunction. This autonomic dysfunction
may contribute to the peripheral vasodilatation of cirrhosis.
Increased adrenergic tone and an increase in plasma catechol-
amines in advanced cirrhosis may contribute to renal vasocon-
striction and augment renal salt retention.
False neurotransmitters may contribute to autonomic dys-
function in cirrhosis, but probably do not dominate in the
kidney since they would be expected to dilate rather than
constrict the renal circulation.
(3) Role of prostaglandins in volume regulation in cirrhosis
(Table 5), Immersion of sodium-retaining patients with cirrhosis
may cause a parallel increase in sodium excretion and urinary
prostaglandin E excretion [70]. Also, administration of prosta-
glandin synthetase inhibitors to patients with decompensated,
but not compensated, cirrhosis results in a sharp fall in glomeru-
lar filtration, renal plasma flow,and sodium excretion [71].
Moreover, the administration of inhibitors of prostaglandin
synthetase may cause a syndrome which mimics hepatorenal
syndrome. Thus, the intrarenal vasodilatory action of prosta-
glandin E seems to be important in the defense of the compro-
mised renal circulation in cirrhosis. Interestingly, however,
administration of prostaglandin synthetase inhibitors to cirrhot-
ic patients can partially correct the excessive hyperreninemia
and hyperaldosteronism as well as the pressor resistance to
angiotensin II. It is not clear at present whether this improve-
ment in angiotensin pressor resistance following administration
of prostaglandin synthetase inhibitors is due to suppression of
endogenous angiotensin II or to inhibition of local arteriolar
synthesis of vasodepressor prostaglandins [71]. Also, there is
controversy as to whether urinary prostaglandin E excretion is
increased [71] or decreased [72, 73] in decompensated cirrhosis.
In summary, increased synthesis of vasodepressor prosta-
glandins in nonrenal arteriolar walls may contribute to the
peripheral vasodilatation and thus "underfilling" in cirrhosis.
Table 5.
tone
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On the other hand, however, increased intrarenal production of
prostaglandin E may be an important defense against powerful
vasoconstrictor influences in cirrhosis. Thus, administration of
prostaglandin synthetase inhibitors may improve the "underfihl-
ing" in the cirrhotic patient but at the same time may worsen
the renal failure.
(4) Role of kallikrein-kinin system in the sodium balance in
cirrhosis. Infusion of kinins into humans and dogs augments
renal blood flow and urinary excretion of sodium [74, 751. Since
plasma prekallikrein and bradykinin levels are subnormal in
patients with cirrhosis [76], it has been suggested that suppres-
sion of the kallikrein-kinin system may contribute to the renal
vasoconstriction in cirrhosis. No information, however, is
available concerning changes in intrarenal activity of the kalli-
krein-kinin system in the kidney in cirrhosis.
(5) Role of natriuretic hormone in salt retention of cirrhosis.
Patients with cirrhosis [77] and dogs with chronic bile duct
ligation [63] lose the ability to "escape" from the sodium-
retaining influence of administered mineralocorticoids. This
finding has raised the possibility that liver disease is associated
with diminished production of natriuretic hormone. This led
Kramer [78] and Wilkinson et al [79] to examine the presence of
antinatriuretic activity in plasma and urine of patients with
cirrhosis. Utilizing various bioassay systems these authors
found diminished antinatriuretic activity in volume expanded
patients with cirrhosis.
It has been suggested recently that the natriuretic hormone
has vasoconstrictor properties [80, 81]. Moreover, an increase
in the circulating level of natriuretic hormone has been suggest-
ed to explain an increase in blood pressure and exaggerated
natriuresis following volume expansion in essential hyperten-
sion. It is therefore tempting to speculate that reduction in
circulating natriuretic hormone associated with liver disease
contributes to the peripheral vasodilatation and hypotension of
cirrhosis as well as the renal sodium retention.
(6) Role of vasoactive intestinal peptide. A vasoactive factor
isolated from the small intestine has biological activity that
mimics many of the associated circulatory and metabolic disor-
ders of cirrhosis [82, 83]. Among these are peripheral vasodila-
tation, increased cardiac output, pulmonary shunting, and
hyperventilation. Since this substance is inactivated by the liver
[83], it has been suggested that in cirrhosis enough vasoactive
intestinal peptide may escape inactivation by the diseased liver
and enter the systemic circulation, thereby contributing to the
circulatory disorder.
(7) Role of cholemia in the circulatory disturbance of cirrho-
sis. Acute intravenous [84] or intrarenal [85] infusion of diluted
bile in dogs causes natriuresis and kaliuresis. The bile compo-
nent responsible for this effect is bile salts rather than bilirubin.
However, isolated chronic cholemia induced in dogs by chole-
dochocaval anastomosis results in peripheral vasodilatation,
hypotension, and sodium retention [86]. Under these chronic
conditions the depressor effect of cholemia on the circulation
overrides the natriuretic properties of bile present in the circula-
tion. Thus, when jaundice complicates cirrhosis peripheral
vasodilatation may aggravate "underfilling" of the circulation.
(8) Role of vasopressin in water retention in cirrhosis. An
impaired ability to excrete a water load and hyponatremia are
common accompaniments of patients with decompensated cir-
rhosis. Several maneuvers which increase central blood volume
and enhance fluid delivery to the nephron, including infusion of
mannitol [87], saline [87], saline plus albumin [21], ascites fluid
[88], saline plus albumin [21], and water immersion to the neck
[29] have been shown to improve urinary dilution and water
excretion in patients with cirrhosis. These results have been
interpreted by some investigators to suggest that intrarenal
mechanisms are responsible for the impaired water excretion of
cirrhosis. These maneuvers which cause volume expansion,
however, could also suppress nonosmotic (baroreceptor-medi-
ated) release of arginine vasopressin and thereby facilitate
water excretion. Some support for the latter possibility are the
findings that administration of alcohol to suppress vasopressin
release [89] or demeclocycline which antagonizes the peripheral
action of vasopressin [90, 91] improves renal water excretion in
cirrhotic patients. Moreover, in experimental liver congestion
[92], portal hypertension [48], common bile duct ligation [49],
and cirrhosis [93], impaired water excretion has been demon-
strated to be primarily due to nonosmotic vasopressin release.
Recent studies by Bichet et al [55, 56] also support an
important role for vasopressin in the water retention associated
with cirrhosis. On the basis of the ability to excrete a 20-mi/kg
water load, the cirrhotic patients could be divided prospectively
into two groups, "excretors" who excreted more than 80% of
the water load in 5 hr and "nonexcretors" who excreted a mean
of only 27% of the water load in 5 hr. The nonexcretor group
had lower serum sodium and osmolalities and higher plasma
vasopressin levels after the water load. Evidence for a decrease
in "effective" blood volume which would be expected to
stimulate baroreceptor-mediated vasopressin release included
lower plasma albumin concentration, higher heart rates, higher
plasma renin activity, plasma aldosterone, and plasma catechol-
amines in the nonexcretor patients. Moreover, water immersion
to the neck enhanced central blood volume, decreased plasma
vasopressin and improved the nonexcretor cirrhotic patients'
capacity to excrete a water load [94]. Thus, it seems clear that
the nonosmotic release of vasopressin, in addition to any
intrarenal mechanism, is important in the impaired water excre-
tion of cirrhosis, Decreased hepatic metabolism of vasopressin
could also contribute to elevated plasma vasopressin levels in
cirrhotic patients. Whether or not vasopressin also exerts a
vascular effect in cirrhotic patients remains to be investigated.
Conclusion
In conclusion, we would like to propose an integrated hy-
pothesis for sodium and water retention in the cirrhotic patient
(Fig. 1). We believe that neither the "overflow" nor "underfill-
ing" theories of sodium retention and ascites are alone ade-
quate to explain totally the observed phenomena in the cirrhotic
patient. It is proposed that both a decrease in "effective" blood
volume with secondary renal sodium retention and primary
renal sodium retention (perhaps initiated by increased intrahe-
patic pressure) are involved in cirrhosis.
Because the absence of intrahepatic pressure elevation sec-
ondary to a side-to-side, but not end-to-end, portal caval shunt
abolishes renal sodium retention in experimental toxic cirrhosis
(Levy, unpublished observation), it can be suggested that
elevated intrahepatic pressure provides the afferent stimulus for
"primary" renal sodium retention in the "overflow" theory of
ascites formation. Portal venous hypertension in the dog, an
expected accompaniment of intrahepatic pressure elevation,
has been shown to increase both renal sympathetic and plasma
renin activity [48]. Moreover, a decrease in "effective" blood
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Fig. 1. Hypothesis for sodium and water retention in
cirrhosis.
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volume in cirrhosis secondary to peripheral vasodilatation, and
enhanced by hypoalbuminemia and splanchnic venous pooling,
would be expected to stimulate the sympathetic nervous sys-
tem. In this regard, patients with decompensated cirrhosis and
ascites have been shown recently to have substantially elevated
levels of plasma norepinephrine levels [56]. Renal venous
catecholamine levels have also been shown to be higher than
peripheral plasma norepinephrine concentrations in cirrhotic
patients [951. The presence of higher pulse rates and plasma
norepinephrine levels in decompensated versus compensated
cirrhotic patients also support a physiologically important acti-
vation of the sympathetic nervous system.
Thus, there is substantial evidence for the central role of
activation of the sympathetic nervous system as proposed in the
present hypothesis for sodium and water retention in cirrhosis.
Moreover, the resultant renal nerve stimulation is proposed to
stimulate renin release as well as decrease GFR and renal blood
flow. The effect of angiotensin II to decrease glomerular
capillary permeability, probably by constricting mesangial cells
and decreasing glomerular capillary surface area, is well docu-
mented [961. Also, the effect of renal nerve stimulation to
increase proximal tubular sodium reabsorption has also been
demonstrated in micropuncture studies [97]. Angiotensin II
receptors have also been found on isolated proximal tubule cells
and may also enhance proximal tubular sodium reabsorption
[981. This effect, however, needs further documentation. The
resultant decrease in distal sodium delivery, secondary to a
lowered filtered load of sodium and enhanced proximal sodium
reabsorption as caused by renal nerve stimulation and increased
angiotensin II, is proposed as the cause for failure of cirrhotic
patients to "escape" from the sodium-retaining effect of aldos-
terone. Thus, neither enhanced proximal sodium reabsorption
nor increased aldosterone-mediated distal sodium reabsorption
alone, but rather both in combination, are proposed to account
for renal sodium retention in cirrhosis. The nonosmotic release
of vasopressin and diminished distal fluid delivery are proposed
to account for the renal water retention in cirrhosis.
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